tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

VRCA Stock Latest News

Verrica Pharmaceuticals initiated with a Buy at Jefferies
The FlyVerrica Pharmaceuticals initiated with a Buy at Jefferies
3d ago
VRCA
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
Press ReleasesVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
18d ago
VRCA
Verrica Pharmaceuticals reports Q4 EPS (14c), consensus (19c)
The FlyVerrica Pharmaceuticals reports Q4 EPS (14c), consensus (19c)
18d ago
VRCA
Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
Press ReleasesVerrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
24d ago
VRCA
Verrica: FDA accepts  filing of VP-102 resubmitted NDA for molluscum treatment
The FlyVerrica: FDA accepts filing of VP-102 resubmitted NDA for molluscum treatment
25d ago
VRCA
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
Press ReleasesVerrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
25d ago
VRCA
Verrica Pharmaceuticals prices $32.5M offering of common stock/warrants at $6.75
The FlyVerrica Pharmaceuticals prices $32.5M offering of common stock/warrants at $6.75
1M ago
VRCA
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Press ReleasesVerrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
1M ago
VRCA
RBC upgrades Verrica Pharmaceuticals to Outperform on improved VP-102 view
The FlyRBC upgrades Verrica Pharmaceuticals to Outperform on improved VP-102 view
1M ago
VRCA
Verrica upgraded to Outperform from Sector Perform at RBC Capital
The FlyVerrica upgraded to Outperform from Sector Perform at RBC Capital
1M ago
VRCA
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Press ReleasesVerrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
2M ago
VRCA
Verrica Pharmaceuticals resubmits NDA for VP-102 in molluscum contagiosum
The FlyVerrica Pharmaceuticals resubmits NDA for VP-102 in molluscum contagiosum
2M ago
VRCA
Verrica Pharmaceuticals announces technology transfer to Piramal Pharma
The FlyVerrica Pharmaceuticals announces technology transfer to Piramal Pharma
3M ago
VRCA
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Press ReleasesVerrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
3M ago
VRCA
Verrica Pharmaceuticals reports Q3 EPS 7c, consensus (11c)
The FlyVerrica Pharmaceuticals reports Q3 EPS 7c, consensus (11c)
5M ago
VRCA
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
Press ReleasesVerrica Pharmaceuticals Reports Third Quarter 2022 Financial Results
5M ago
VRCA
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
Press ReleasesVerrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
7M ago
VRCA
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Press ReleasesVerrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
8M ago
VRCA
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
Press ReleasesVerrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
8M ago
VRCA
Why Did Shares of Verrica Pharmaceuticals Gain 15%?
Market NewsWhy Did Shares of Verrica Pharmaceuticals Gain 15%?
9M ago
VRCA
Verrica Announces Pricing of Public Offering of Common Stock
Press ReleasesVerrica Announces Pricing of Public Offering of Common Stock
9M ago
VRCA
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
Press ReleasesVerrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
9M ago
VRCA
3 Biotech Stocks With Strong Catalysts in September
Stock Analysis & Ideas3 Biotech Stocks With Strong Catalysts in September
2y ago
CALT
VRCA
Analysts Bullish on Verrica Ahead of Ycanth Launch
Stock Analysis & IdeasAnalysts Bullish on Verrica Ahead of Ycanth Launch
2y ago
VRCA
RBC Capital: 3 Stocks to Buy With Over 50% Upside Potential
Stock Analysis & IdeasRBC Capital: 3 Stocks to Buy With Over 50% Upside Potential
2y ago
SGMO
VRCA
FDA Extends Review Period for Verrica Pharmaceuticals’ VP-102 Drug Application
Market NewsFDA Extends Review Period for Verrica Pharmaceuticals’ VP-102 Drug Application
2y ago
VRCA
2 “Strong Buy” Stocks Insiders Are Snapping Up
Stock Analysis & Ideas2 “Strong Buy” Stocks Insiders Are Snapping Up
2y ago
EPZM
VRCA
Verrica Resubmits FDA Drug Application For Skin Therapy; Street Sees 63% Upside
Market NewsVerrica Resubmits FDA Drug Application For Skin Therapy; Street Sees 63% Upside
2y ago
VRCA
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.